Experiments on patients, processes or plants all have random error, making statistical methods essential for their efficient design and analysis. This book presents the theory and methods of optimum experimental design, making them available through the use of SAS programs. Little previous statistical knowledge is assumed. The first part of the book stresses the importance of models in the analysis of data and introduces least squares fitting and simple optimum experimental designs. The second part presents a more detailed discussion of the general theory and of a wide variety of experiments. The book stresses the use of SAS to provide hands-on solutions for the construction of designs in both standard and non-standard situations. The mathematical theory of the designs is developed in parallel with their construction in SAS, so providing motivation for the development of the subject. Many chapters cover self-contained topics drawn from science, engineering and pharmaceutical investigations, such as response surface designs, blocking of experiments, designs for mixture experiments and for nonlinear and generalized linear models. Understanding is aided by the provision of "SAS tasks" after most chapters as well as by more traditional exercises and a fully supported website. The authors are leading experts in key fields and this book is ideal for statisticians and scientists in academia, research and the process and pharmaceutical industries.

Few scientific developments have given rise to as much controversy as biotechnology. Numerous groups are united in their opposition, expressing concern over environmental and health risks, impacts on rural livelihoods, the economic dominance of multinational companies and the ethical implications of crossing species boundaries. Among the supporters of the technology are those that believe in its potential to enhance food security, further economic development, increase productivity and reduce environmental pressures. As a result, countries - and sectors within countries - find themselves at odds with each other while potential opportunities for development offered by the use of biotechnology are seized or missed, and related risks go unmanaged. This book, a unique interdisciplinary collection of perspectives from the developing world, examines the ongoing debate. Writing for the International Centre for Trade and Sustainable Development, leading experts address issues such as diffusion of technology, intellectual property rights, the Cartagena Protocol, impacts of international trade, capacity building and biotechnology research and regulation. With the most recent and relevant examples from around the world, Trading in Genes offers the reader a single-volume overview of the connections between biotechnology, trade and sustainability that is both wide-ranging and thorough

Democratizing Technology provides a much-needed fresh perspective on the regulation of chemicals, and an important contribution to green thinking about technology.Caroline Lucas, Green Party MEP. This book is an excellent critique of the current risk-based approach to technology. By exploring the philosophical underpinnings and the practical applications of current policy on science and technology, Chapman exposes the serious flaws in allowing economic considerations to dominate the agenda in this area. Her proposals for reform are expertly constructed and deserve urgent and serious consideration by policy-makers.Dr Stuart Parkinson, Executive Director, Scientists for Global Responsibility. In this important book Anne Chapman argues that decisions about technology should answer a republican question: what kind of public world should we create through technology? Democratizing Technology deserves to be read widely. John ONeill, Professor of Political Economy, University of Manchester, UK A welcome addition to the new, more empirical and applied literature in philosophy of technology. This book will be essential reading for a variety of scholars and for the general reader intent on understanding, and criticizing, our chemically made world.Andrew Light, Interim Director, Program on the Environment, University of Washington, US What is technology? How do humans use it to build and modify the world? What are the relationships between technology, science, economics and democratic governance? What, if any, are our ethical and political responsibilities and choices in how we develop, deploy and control technology in democratic states? Democratizing Technology sets out to answer these questions. Focusing on the most widespread and pervasive technology - chemicals - this groundbreaking volume peels apart the critical technology debate to look at the relationship between humans, technology and the biological world. Attention is given to the immensely important new regulations, REACH (Registration, Evaluation, Authorization and restriction of Chemicals), the EUs largest ever legal framework, discussing the problems that are likely to occur in REACHs reliance on risk assessment methods and suggesting an alternative way forward for the regulation of chemicals. Providing much-needed clarity and insight into the heart of key debates in science and technology, risk analysis and mitigation, and domestic and international law, this volume arrives as a breath of fresh air.

Sustaining the new bioeconomy requires a global biotechnology governance regime to bring a large number of developing countries into the global trading system. Failure to do so will create a "genetic divide" among countries and is likely to intensify public opposition to biotechnology. This unique interdisciplinary collection of perspectives from the developing world on the debates over the relationships between biotechnology, biosafety, sustainable development and trade seeks to bridge the gap between the different areas of regulatory activities and academic research, and between the various stakeholders in the debate. Leading experts, writing for the influential International Centre for Trade and Sustainable Development, examine: the risks and opportunities of biotechnology; biosafety; intellectual property rights and related issues of access to genetic resources, benefit-sharing and traditional knowledge; biotechnological development; capacity building; the Cartagena Protocol on Biosafety; relevant WTO provisions; and developing countries' options in the WTO context.

This book was written with aim of providing some insights into the process of the buyout of Exxon Chemicals--the first such buyout in Pakistan's corporate history. It also tells the story of one person's endeavor to make his vision a reality. The man who spearheaded the buyout is Shaukat Raza Mirza. In this book, we are gripped by corporate drama as the story of the buyout unfolds. Shaukat's primary role is central, as he relates the discussions, decisions, and challenges faced.